3SBio Gelecekteki Büyüme

Future kriter kontrolleri 3/6

3SBio kazanç ve gelirin sırasıyla yıllık 16.4% ve 9.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 15.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.4%

Kazanç büyüme oranı

15.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.4%
Gelir büyüme oranı	9.6%
Gelecekteki özkaynak getirisi	13.3%
Analist kapsamı	Good
Son güncelleme	18 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Oct 08

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

Oct 07

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

Kazanç ve Gelir Büyüme Tahminleri

SEHK:1530 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	10,719	2,580	1,779	3,032	8
12/31/2025	9,769	2,317	1,554	2,745	9
12/31/2024	8,909	2,019	1,116	2,460	8
6/30/2024	8,422	1,659	1,297	1,991	N/A
3/31/2024	8,119	1,604	1,338	2,037	N/A
12/31/2023	7,816	1,549	1,379	2,083	N/A
9/30/2023	7,686	1,739	1,321	2,187	N/A
6/30/2023	7,555	1,929	1,264	2,291	N/A
3/31/2023	7,210	1,923	1,212	2,213	N/A
12/31/2022	6,866	1,916	1,159	2,134	N/A
9/30/2022	6,618	1,817	1,008	1,964	N/A
6/30/2022	6,369	1,719	856	1,794	N/A
3/31/2022	6,376	1,685	663	1,686	N/A
12/31/2021	6,382	1,651	469	1,578	N/A
9/30/2021	6,191	1,342	394	1,513	N/A
6/30/2021	6,000	1,032	318	1,448	N/A
3/31/2021	5,794	934	340	1,396	N/A
12/31/2020	5,588	836	363	1,345	N/A
9/30/2020	5,479	1,095	813	1,620	N/A
6/30/2020	5,370	1,355	1,263	1,896	N/A
3/31/2020	5,344	1,164	1,332	1,892	N/A
12/31/2019	5,318	974	1,401	1,887	N/A
9/30/2019	5,185	1,029	1,257	1,645	N/A
6/30/2019	5,053	1,084	1,113	1,403	N/A
3/31/2019	4,818	1,181	915	1,277	N/A
12/31/2018	4,584	1,277	717	1,150	N/A
9/30/2018	4,393	1,167	695	1,160	N/A
6/30/2018	4,202	1,057	673	1,171	N/A
3/31/2018	3,968	996	N/A	1,122	N/A
12/31/2017	3,734	935	N/A	1,074	N/A
9/30/2017	3,467	877	N/A	1,017	N/A
6/30/2017	3,199	818	N/A	960	N/A
3/31/2017	2,998	766	N/A	982	N/A
12/31/2016	2,797	713	N/A	1,004	N/A
9/30/2016	2,492	642	N/A	794	N/A
6/30/2016	2,188	571	N/A	583	N/A
3/31/2016	1,930	548	N/A	519	N/A
12/31/2015	1,673	526	N/A	455	N/A
9/30/2015	1,503	456	N/A	521	N/A
6/30/2015	1,364	341	N/A	534	N/A
3/31/2015	1,247	316	N/A	460	N/A
12/31/2014	1,131	292	N/A	387	N/A
9/30/2014	1,044	238	N/A	301	N/A
12/31/2013	875	96	N/A	217	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1530 'nin tahmini kazanç büyümesi (yıllık 16.4% ) tasarruf oranının ( 2.3% ) üzerindedir.

Kazançlar ve Piyasa: 1530 şirketinin kazançlarının (yıllık 16.4% ) Hong Kong pazarından (yıllık 11.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 1530 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 1530 şirketinin gelirinin (yıllık 9.6% ) Hong Kong pazarından (yıllık 7.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1530 şirketinin gelirinin (yıllık 9.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1530 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.3 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/21 08:46
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

3SBio Inc. 34 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Sharon Shi	BOCI Research Ltd.
Ruyi Tang	BOCI Research Ltd.
Difei Yang	Capstone Investments

3SBio Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

Consensus EPS estimates fall to CN¥0.52

Recent updates

Investor sentiment deteriorates as stock falls 17%

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

First half 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment improved over the past week